AU744272B2 - Method for preparing alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds - Google Patents
Method for preparing alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds Download PDFInfo
- Publication number
- AU744272B2 AU744272B2 AU86333/98A AU8633398A AU744272B2 AU 744272 B2 AU744272 B2 AU 744272B2 AU 86333/98 A AU86333/98 A AU 86333/98A AU 8633398 A AU8633398 A AU 8633398A AU 744272 B2 AU744272 B2 AU 744272B2
- Authority
- AU
- Australia
- Prior art keywords
- formula
- furanone
- compounds
- acid
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
Description
METHOD FOR PREPARING ALKOXY FURANONE DERIVATIVES, COMPOUNDS OBTAINED BY SAID METHOD AND USE OF SAID
COMPOUNDS
The present invention relates to a novel process for preparing alkoxyfuranoneamine derivatives, to the compounds obtained by this process, and to the use of these compounds in the synthesis of inhibitors of interleukin-lbeta converting enzyme.
Patent Applications WO 95/35308, WO 97/22619, WO 97/22618, EP 519 748 and WO 96/33209 describe compounds which inhibit interleukin-lbeta converting enzyme.
The process for preparing some of the compounds described in the patent applications mentioned above uses the compounds of the formula below: i ':HN OCH 2
R
2 2
R
1 0 O O in which RI represents an ethyl radical and R2 represents a -CH=CH2 radical.
I The compounds of the formula are prepared from protected L-aspartic acid and require 4 synthetic steps: 1) acylation, 2) reduction, 3) oxidation, 4) cyclization, (Chapman K.T. et al., Bioorg. Med. Chem. Lett. 613-8 (1992 This process has major drawbacks, in particular when it is desired to obtain chiral compounds of the formula (I) More specifically, an expensive chiral starting reagent, fl-tert-butyl L-aspartate, has to be used, and above all chromatographic methods have to be used to isolate and/or purify the various diastereoisomers.
One object of the present invention is thus to find another route for the synthesis of the compounds of the formula which avoids the use of this starting material and which does not require chromatographic separations The Applicant thus proposes a novel synthetic route starting with the alkoxyfuranone of formula in racemic form, giving access to the novel compounds of the formulae (IVa), (IVb), (IVc) or (IVd) as defined below, in salified or non salified form, which are then protected, where necessary, in order in particular to obtain the compounds of the formula This process has the advantage of being able to be carried out on large scale, starting with a readily accessible and inexpensive compound of the formula with the separation and/or purification stages being carried out by crystallization rather than by chromatography. Each diastereoisomer of the formula (III), (IV) or can thus be isolated.
The present invention thus relates, on the one hand,to the compounds of the formula (IVa), (IVb), (IVc) or (IVd) below: H2 N H 2
N
R S RO O
S
1 0 R R-n. R1 s (Iva) (IVb)
H
2 N
H
2
N
R S S R R0 0 0
R
1 0 O O (Ivc) (IVd) in which Ri is an alkyl group containing from 1 to 4 carbon atoms or a phenylalkyl group containing from 7 to 11 carbon atoms, as well as the addition salts thereof with acids.
The invention naturally extends to the salts of the compounds of formula (IVa), (IVb), (IVc) or (IVd), such as, for example, the salts formed with inorganic or organic acids on the amine. The acids may thus be hydrochloric, hydrobromic, nitric, sulphuric, phosphoric, acetic, formic, propionic, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic or aspartic acid, alkanesulphonic acids such as methanesulphonic or ethanesulphonic acid, arylsulphonic acid, such as benzenesulphonic or paratoluenesulphonic acid, and arylcarboxylics acids.
They may also be chloroacetic or trichloroacetic acid.
Most particularly, they are salts formed with hydrochloric acid.
When RI is an alkyl group containing 1 to 4 carbon atoms, it can be, in particular, methyl, ethyl, butyl or propyl, and most particularly ethyl.
The term "phenylalkyl", preferably refers to the benzyl group.
The invention more particularly relates to the compound of the formula (IVd) as defined above, as well as the addition salts thereof with acids.
The invention most particularly relates to the compounds of the formula (IVd) in which R 1 is an ethyl group, as well as the addition salts thereof with acids.
Moreover, the present invention relates to a process for preparing compounds of (IVa), (IVb), (IVc) or (IVd) as described above, characterized in that it comprises at least one of the following steps: action of an arylamine of the formula R 3
R
4
CHNH
2 wherein
R
3
R
4
CHNH
2 is either of R or S conformation, in which R 3 is a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms and R 4 is an optionally substituted aryl, on the racemic alkoxyfuranone of the formula (II):
(II)
R
1 0 O O S in which R 1 is an alkyl group containing from 1 to 4 carbon atoms or a phenylalkyl i** group containing from 7 to 11 carbon atoms, and production of the trans isomer compounds (4R, 5R) and (4S, 5S) of the formulae (Ilia) and (Illb) respectively: 18/12/01,all 1068.spc,4
R
3 R3 HN R HN R 4 R S
R
1 0 O R 1 0 O (IIIa) (IIIb) which subsequently are separated by crystallization, carrying out, if necessary, one or more salification reactions, or, when R3 is a hydrogen atom, are resolved by the action of an optically active acid, b) where appropriate, epimerization reaction on the compound of the formula (IIIa) or (IIIb),in salified or non salified form, in the presence of an acid, in order to obtain the cis isomer compounds(4R,5S) or (4S,5R) of the formula (IIIc) or (IIId), which are salified if necessary, R R HN R4 HN R 4
R
1 0 0 0 R 1 0 R0 0 (IIIc) (IIId) c) hydrogenolysis reaction, either on the trans isomer (4R,5R) or (4S,5S) of the formula (IIIa) or (IIIb), in salified or non salified form, in order to obtain the compound of the formula (IVa) or (IVb) in the form of the trans isomer (4R,5R) or (4S,5S) as defined above, which is then, if necessary, salified and/or protected, or on the cis isomer (4R,5S) or (4S,5R) of the formula (IIIc) or (IIId),in salified or non salified form, in order to obtain the compound of the formula (IVc) or (IVd) in the form of the cis isomer (4R,5S) or (4S,5R), as defined above, which is, if necessary, salified, and/or protected.
In particular the reaction for protecting the amines of the formula (IVa), (IVb), (IVc) or (IVd), in salified or non salified form, is carried out by the action of the chloroformate of the formula C1-CO-O-CH2-R2, R2 representing a tert-butyl, (C2-C4)-alkenyl, (C2-C4)-alkynyl or phenyl radical, which may be substituted or unsubstituted, in order to obtain the compounds of the formula (Ic) or (Id) respectively, in the form of the trans diastereoisomers (4S,5S) or the cis diastereoisomers (4R,5S) and which, if necessary are salified, 0 HN OCH 2
R
2 HN OCH 2
R
2
R
S
R
1 0 O O Ri1 0 (Ia) (Ib) 0 HN
OCH
2
R
2 2 HN OCH2R 2 SR
R
R101 1 0 0 R1R 1 0 0 0 (Ic) (Id) The action of the arylamine R3R4CHNH2 on the racemic alkoxyfuranone of the formula (II) is carried out according to the standard methods required for the Michael reaction, that is to say, in particular, in a dipolar aprotic solvent, such as dimethylformamide, at room temperature. The process can also be performed with the R or S phenylethylamine or in aqueous isopropanol.
The separation of the two trans isomers (4R,5R) and i.e. the compounds of the formulae (IIIa) and (IIIb) respectively, by crystallization is carried out according to the methods known to those skilled in the art concerning the separation of isomers. As a preferred example, the separation is carried out by the action of trichloroacetic acid in a solvent such as tert-butyl methyl ether or aqueous isopropanol. The trans isomer (4R,5R) (IIIa) is crystallized in the form of the trichloroacetic acid salt, while the trans isomer (4S,5S) (IIIb) is recovered in the form of the monochloroacetic acid salt by treatment of the mother liquors in the presence of monochloroacetic acid.
When R3 is a hydrogen atom (non-chiral amine), the separation (resolution) is then carried out by means of a chiral acid such as tartaric acid camphorsulphonic acid, salicylic acid, dibenzoyltartaric acid or R' 2,4hydroxyphenoxypropionic acid.
The epimerization reaction on one of the isomers or (4S,5S) of the formula (IIIa) or (IIIb) is carried out in the presence of a Lewis acid such as ferric chloride or titanium tetrachloride optionally complexed with tetrahydrofuran, boron trichloride, boron trifluoride etherate and tin tetrachloride or of an organic acid, such as methanesulphonic acid, trifluoroacetic acid or para-toluenesulphonic acid. It is preferably tin tetrachloride, in the presence of a relatively non-polar solvent, such as dichloromethane, or methanesulphonic acid in a solvent, such as toluene.
The hydrogenolysis reaction on the cis or trans diastereoisomer of the formula (IIIa), (IIIb), (IIIc) or (IIId), is carried out according to the standard methods known to those skilled in the art, for example by the action of hydrogen in the presence of 10% palladium-on-charcoal in tetrahydrofuran.
The acylation reaction with the chloroformate is preferably carried out in the presence of a base, such as pyridine, in a relatively non-polar solvent, such as dichloromethane.
The formation of the base from the corresponding salt, i.e. the return to the free amine, and the methods of salification with the acids as defined above are carried out according to the methods known to those skilled in the art.
As regards the compounds of the formula (III) when R3 is an alkyl group containing from 1 to 4 carbon atoms, it is preferably methyl or ethyl and when R4 is an aryl group, it is preferably phenyl or naphthyl.
As regards the compounds of the formula when R2 is a (C2-C4) alkenyl or (C2-C4) alkynyl group, it is preferably -CH=CH2,-CCH, -CH=CH2-CH3, or -C C-CH3.
The protection reactions of the compounds of the formula are carried out according to the methods known to those skilled in the art, and in particular with reference to the WO 99/03852 9 PCT/FR98/01480 book by Philip J. Kociensky, Protecting Groups, Ed. Georg.
Thieme Verlag, Stuttgart New-York, 1994.
The present invention more particularly relates to the process as defined above, characterized in that the separation, by crystallization, of the compounds of the formulae (IIIa) and (IIIb) is carried out: a) by the action of trichloroacetic acid, in order to obtain the corresponding salt of the formula (IIIa) or (IIIb), b) followed by the action of monochloroacetic acid on the mother liquors, in order to obtain the salt corresponding to the other diastereoisomer of the formula (IIIa) or (IIIb).
The present invention most particularly relates to a process for preparing, as described above, the compounds of the formula (IVd) or (Id) as defined above, characterized in that it comprises at least one of the following steps: a) action of the R phenylethylamine on the compound of the formula in order to obtain the compounds of the formulae (III'a) and (III'b) below
HN
SHN
C
6
H
R
R 1 0 0 0 S
R
1 0 O O (III'a) (III'b) b) separation of trans stereoisomers of the formulae (III'a) and (III'b) by the action of trichloroacetic acid, in order to obtain the stereoisomer (III'b) (4S 5S) in the form of the trichloroacetic acid salt, followed by the action of monochloroacetic acid, in order to obtain the stereoisomer WO 99/03852 10 PCT/FR98/01480 (III'a) (4R,5R) in the form of the monochloroacetic acid salt, c) where appropriate, return to the free amine by the action of a base, c) epimerization reaction on the stereoisomer (4S,5S) of the formula (III'b) in the presence of an acid, in order to obtain a cis stereoisomer (4S,5R) of the formula (III'd) HN C 6
H
(III'd)
R
R
1 0 0 0 e) if necessary, crystallization after salification by the action of an acid, such as monochloroacetic acid or dichloroacetic acid, f) where appropriate, return to the free amine by the action S: of a base, g) if necessary, recrystallization after salification, in particular in the form of the hydrochloride, h) hydrogenolysis of the cis stereoisomer (4S,5R) of the formula (III'd), in order to obtain the compound of the formula (IVd) in the form of the cis diastereoisomer i) where appropriate, the action of allyl chloroformate on the compound of the formula (IVd), in order to obtain the compound of the formula (Id) in the form of the cis diastereoisomer (4S,5R), with Ri representing -CH=CH2.
The invention also relates most particularly to a process for preparing, as described above, compounds of the formula (IVd) or (Id) as defined above, characterized in that it comprises at least one of the following steps WO 99/03852 PCT/FR98/01480 a) action of the S phenylethylanine on the compound of the formula in order to obtain the compounds of the formulae (III"a) and (III"b) below: HN C H 5
R
R
Rio 0 0 HN z C H a a a a a a a a a.
a a *a a. a a a a.
a a a Rio 011 (III" a) (III" b) b) resolution of the trans stereoisomers of the formulae (III"a) and (III"b) by the action of trichloroacetic acid, in order to obtain the stereoisomer (III"a) (4R,5R) in the form of the trichloroacetic acid salt, followed by the action of monochloroacetic acid, in order to obtain the stereoisomer (III11b) (4S,5S) in the form of the monochloroacetic acid salt, c) if necessary, return to the free amine by the action of a base, d) epimerization reaction on the stereoisomer (4S,5S) of the formula (III"b) in the presence of an acid, in order to obtain a cis diastereoisomer (4S,5R) of the formula (III"d): HN
C
6
H
S
R (III"d) 0 O e) if necessary, crystallization after salification by the action of an acid, such as monochloroacetic acid or dichloroacetic acid, f) where appropriate, return to the free amine by the action of a base, g) if necessary recrystallization after salification, in particular in the form of the hydrochloride, h) hydrogenolysis of the cis stereoisomer (4S,5R) of the formula (III"d), in order to obtain the compound of the formula (IVd) in the form of cis diastereoisomer i) where appropriate, the action of allyl chloroformate on the compound of the formula (IVd), in order to obtain the compound of the formula (Id) in the form of the cis diastereoisomer The invention most particularly relates to the process as defined above, characterized in that the addition of the amine to the compound of the formula (II) is carried out in dimethylformamide or in aqueous isopropanol.
The invention most particularly relates to the process as defined above, characterized in that the epimerization reaction is carried out with tin tetrachloride or methanesulphonic acid.
The invention most particularly relates to the process as defined above, characterised in that Ri is an ethyl radical.
The invention most particularly relates to the process as defined above, characterized in that the separation of the trans stereoisomers with trichloroacetic acid (step b) is carried out in aqueous isopropanol.
The invention most particularly relates to the process using the phenylethylamine characterized in that the epimerization reaction on the stereoisomer (4S,5S) of the formula (III"b) (step d) is carried out in the presence of methanesulphonic acid in toluene.
The invention most particularly relates to the process using the phenylethylamine, characterized in that the crystallization (step e) is carried out by the action of dichloroacetic acid in toluene.
The invention also relates to the use: either of the compounds of the formula (IVa), (IVb), (IVc) or (IVd) as defined above or obtained from the process as described above, or of the compounds of the formula (Ic) or (Id) obtained from the process as described above, in amidation reactions, starting with the acid of the formula A-COOH, to give a compound of the formula below:
H
A-C-N
I
0
(V)
R)
1 0 0 0 A representing any organic radical.
The invention also relates to the use: either of the compounds of the formula (IVb) or (IVd) as defined above or obtained from the process as described above, or of the compounds of the formula (Ib) or (Id) obtained from the process as defined above, in the synthesis of the compounds of the formula which have inhibitory activity on interleukin converting enzyme.
These compounds of the formula are in described in particular in the patent applications WO 95/35308, WO 97/22619, EP 0 519 748 and WO 96/33209.
The invention most particularly relates to the use: either of the compound of the formula (IVd) in which Ri ethyl, as defined above or obtained from the process as described above, or of the compound of the formula (Id) in which Ri ethyl obtained from the process as described above, in the preparation of a compound of the formula which has inhibitory activity on interleukin converting enzyme.
A subject of the invention is, most particularly, the use: either of the compound of the formula (IVd) in which Ri ethyl as defined above or obtained from the process as described above, or of the compound of the formula (Id) in which Ri ethyl obtained from the process as described above, in the preparation of the compound of the formula with the following structure: EtO This compound is described in patent application WO 97/22619 (Pdt 412e).
The invention also relates to the compounds of the formulae (IIIa), (IIIb), (IIIc) and (IIId), as well as the addition salts with acids as described above, as novel intermediate compounds, with the exception of the compounds of the formulae (III"a) and (III"b) with Ri methyl.
The compounds of the formula (II) are known or are readily accessible from the methoxyfuranone by the action of PTSA (para-toluenesulphonic acid), in the presence of water, and then of a reagent of the formula (RIO)3CH in the presence of an acidic catalyst.
The examples which follow illustrate the invention without, however, limiting it.
EXAMPLE 1: (2R-cis) 2-propenyl (2-ethoxytetrahydro-5-oxo-3furanyl) carbamate Stage 1: Michael Addition dihydro-5-ethoxy-4 [(1-phenylethyl)amino]-2(3H)furanone ml of 98% R- (+)-phenylethylamine are added over the course of 30 minutes at between 23 and 25 0 C, under an inert atmosphere, to 15 g of racemic ethoxyfuranone in 75 ml of dimethylformamide, and the solution obtained is stirred for 24 hours and then poured into a water/ice mixture. Isopropyl ether is added, and this mixture is extracted, washed, dried and evaporated under reduced pressure to give 27 g of an oil corresponding to the expected 50/50 mixture of the trans isomers.
NMR (CDC13; 250 MHz) 1.12; 1.22 CH2CH3 1.37 (dd) CH3 (-NH-CH(CH3) (Ph)) 2.13 (dd, J=3.5 and 17.5) 2.35 (dd, J=3 and 17.5) CH2 at 3 of the furanone.
2.70 (dd, J= 7.5 and 17.5) 2.80 (dd, J= 7 and 17.5) 3.26 CH at 4 of the furanone 3.30 to 3.90 CH2CH3 3.82 CH (-NH-CH(CH3) (Ph)) 5.00 J=1.5) and 5.32 CH at 5 of the furanone 7.2 to 7.4 5H aromatic Stage 2 Resolution of the two trans diastereoisomers A) production of the trans diastereoisomer 4(S)[4a(S*),5p]-dihydro-5-ethoxy-4-[ (-phenylethyl)amino]- 2(3H)-furanone trichloroacetate A solution of 10.6 g of trichloroacetic acid in ml of tert-butyl methyl ether is added over 20 min. to 27 g of the mixture of diastereoisomers obtained in the above stage in 164 ml of tert-butyl-methyl-ether. The solution obtained is stirred for 2 hours at 20-25C then for 2 hours at 0 C. 12 g of the (4S,5S) isomer are obtained in the form of the trichloroacetic acid salt.
[aD] 710 (c 1% NMR (CDC13 250 MHz) 1.15 CH2CH3 1.75 J=7) CH3 (-NH-CH(CH3) (Ph)) 2.78 (dd, J=8.5 and 18.5) 3.05 (dd, J=4 and 18.5) CH2 at 3 of the furanone.
3.43 (ddd, J=2-4 and 8.5) CH at 4 of the furanone 3.59 (dq, 1H) 3.79 (dq 1H) CH2CH3 4.29 (-NH-CH(CH3) (Ph)) 5.77 J=1,5) CH at 5 of the furanone 7.42 to 7.57 5H aromatic 9.80 (broad) H mobile B) production of the trans diastereoisomer (4R,5R) of 4 (R) ,5p]-dihydro-5-ethoxy-4- (-phenylethyl) amino]-2(3H)furanone chloroacetate The mother liquors from the above stage are washed with saturated sodium bicarbonate solution and then with water, after which they are re-extracted once with isopropyl ether.
After drying, the solution is evaporated under reduced pressure to give 15.45 g of the expected product in the form of an oil. 5 g of monochloroacetic acid is added to the 15.45 g of product in 130 ml of isopropanol, and this mixture is heated to 40 0 C. Dissolution and then crystallization are observed, after which the mixture is stirred for 1 hour at room temperature and then for 2 hours at 0-5 0 C. 11.98 g of the expected (4R,5R) isomer are obtained in the form of the monochloroacetic acid salt.
Stage 3: productionof the desalified (4S,5S) compound 4(S) ,5p] -dihydro-5-ethoxy-4- (1-phenylethyl)amino] 2(3H)-furanone 11.8 g of the salt obtained in Stage 2A and 120ml of dichloromethane are mixed together at room temperature, followed by addition of 100 ml of saturated sodium bicarbonate solution. After stirring for 10 min., the mixture is extracted, washed, dried and evaporated under reduced pressure to give 7.1 g of the desalified product.
[ao] +1140 (c 1% Stage 4: epimerization: production of the diastereoisomer 4(S)[4a(S*),5a]-dihydro-5-ethoxy-4-[(1-phenylethyl)amino]- 2(3H)-furanone 28.6 ml of 1M tin tetrachloride in dichloromethane are added, under an inert atmosphere over 1 hour at 4 1°C, to 6.8 g of the desalified (4S,5S) compound obtained in Stage 3 in 135 ml of dichloromethane, and the mixture is stirred for minutes at this temperature. 11 ml of acetic acid are then added, the mixture is stirred for 30 minutes at 5 0
C,
poured into a water/ice mixture and washed, cyclohexane is added, this mixture is brought to pH 7-8 by addition of sodium bicarbonate, and it is then extracted with cyclohexane, dried and evaporated under reduced pressure to give 4.39 g of the expected product in the form of an oil corresponding to a cis/trans ratio of 90/10.
[aD] -1°5 (c 1% NMR (CDC13 250 MHz) 1.23 CH2CH3 1.40 J=6.5) CH3 (-NH-CH(CH3) (Ph)) 2.39 (dd, J=ll and 17) 2.61 (dd, J=8 and 17) CH2 at 3 of the furanone.
3.32 CH at 4 of the furanone 3.77 CH (-NH-CH(CH3) (Ph)) 4.96 J=5) CH at 5 of the furanone 7.20 to 7.40 5H aromatic Stage 5: formation of the monochloroacetic acid salt of the cis diastereoisomer 4(S) ,5a]-dihydro-5-ethoxy-4-[ (l-phenylethyl)amino]- 2(3H)-furanone chloroacetate 1.82 g of monochloroacetic acid are added, under an inert atmosphere, at 20-25°C to 5 g of the cis diastereoisomer obtained in the above stage in 50 ml of tert-butyl methyl ether. A solution is obtained which crystallizes rapidly, and is left for 1 hour 30 min. at +5 0 C. 5.75 g of the expected product are obtained.
m.p. 106-108 0
C
[aD] -11°5 (c 1% Stage 6: hydrogenolysis a) desalification (return to the free amine) 4(S)[4a ,5a] -dihydro-5-ethoxy-4-[ (-phenylethyl)amino] 2(3H)-furanone 5.55 g of the monochloroacetic salt obtained in the above stage, 60 ml of dichloromethane and 55 ml of sodium bicarbonate are mixed together at 0-5 0 C, under an inert atmosphere, and the mixture is stirred for 10 min., washed, extracted, dried and evaporated under reduced pressure to give 3.95 g of desalified product in the form of an oil.
b) Formation of the hydrochloride 4(S) [4a 5] -dihydro-5-ethoxy-4- (1-phenylethyl) amino] 2(3H)-furanone hydrochloride 6.6 ml of 2N hydrochloric acid in isopropyl ether are added dropwise, at 0-50C to 3.36 g of the product obtained above in 66 ml of isopropyl ether, and the resulting solution is maintained for 1 hour at this temperature. Crystallization is observed. 3.77 g of the expected hydrochloride are obtained.
c) Hydrogenolysis (4(S)-cis)-4-amino-5-ethoxydihydro-2(3H)-furanone hydrochloride 1.8 ml of water are added to a suspension of 4 g of the hydrochloride obtained above in 60 ml of tetrahydrofuran, in order to obtain a solution, followed by addition of 400 mg of palladium-on-charcoal. The mixture is stirred under bar of hydrogen for 18 hours at 27-28 0 C. After filtration and rinsing with a tetrahydrofuran/water mixture, the mixture is evaporated under reduced pressure. 2.54 g of the expected product are obtained.
[aD] -96o (c 1% 1.22 CH2CH3 2.58 (dd, J=8 and 17.5) 2.70 (dd, J=8 and 17.5) CH2 at 3 of the furanone.
4.14 (dt, J=5.5 and 8) CH at 4 of the furanone 3.61; 3.90 CH2CH3 5.71 J=5.5) CH at 5 of the furanone 8.69 (bs) 3H mobile Stage 7: Formation of allyl carbamate (2R-cis) 2-propenyl (2-ethoxytetrahydro-5-oxo-3-furanyl)carbamate 3 ml of pyridine are added, at +5 0 C under inert atmosphere, to a mixture consisting of 2.4 g of the product obtained in the above stage, 50 ml of dichloromethane and 1.55 ml of allyl chloroformate, the resulting mixture is stirred for one hour at this temperature and 0.56 ml of allyl chloroformate and 1 ml of pyridine are then added. This mixture is stirred for 6 hours at room temperature,poured into water, extracted with dichloromethane, washed, dried and evaporated under reduced pressure to give 2.66 g of crude product, which product is recrystallized from isopropyl ether. 1.95 g of pure expected product are obtained.
[aD] -560 (c 1% CH2C12) 1.26 CH2CH3 2.47 (dd, J=10 and 17.5) 2.84 (dd, J=8.5 and 17.5) CH2 at 3 of the furanone 3.67 (dq) and 3.92 (dq) CH2CH3 4.55 CH at 4 of the furanone 4.59 (bd) CH2-CH=CH2 5.45 J=5.5) CH at 5 of the furanone 5.25 (dq) and 5.33 (dq) CH2-CH=CH2 5.30 masked
N-H
5.93 CH2-CH=CH2 EXAMPLE 2: (2R-cis) 2-propenyl (2-ethoxytetrahydro-5-oxo-3furanyl)carbamate Stage 1: Michael Addition 4(S*)dihydro-5-ethoxy-4 [(1-phenylethyl)amino]-2(3H)-furanone ml of 98% S- phenylethylamine is added over min between 23 and 25 0 C, under an inert atmosphere, to 15 g of racemic ethoxyfuranone in 75 ml of dimethylformamide, and the solution obtained is stirred for 24 hours then poured into a water/ice mixture. After extraction with cyclohexane, washing and drying, the solution is evaporated under reduced pressure to give 26.6 g of an oil corresponding to an expected 45/55 mixture of the trans isomers.
NMR (CDC13 250 MHz) 1.12 1.22 CH2CH3 1.37 (dd) CH3 (-NH-CH(CH3) (Ph)) 2.13 (dd, J=3.5 and 17.5) 2.35 (dd, J=3 and 127.5) CH2 at 3 of the furanone 2.70 (dd, J 7.5 and 17.5) 2.80 (dd, J 7 and 17.5) 3.26 CH at 4 of the furanone 3.30 to 3.90 CH2CH3 3.82 CH (-NH-CH (CH3) (Ph)) 5.00 and 5.32 J=1.5) CH at 5 of the furanone 7.2 to 7.4 5H aromatic Stage 2: Resolution of the two trans diastereoisomers a) production of the trans diastereoisomer 4(R)[4a(S*),5p]-dihydro-5-ethoxy-4-[(1-phenylethyl)amino] 2(3H)-furanone trichloroacetate A solution of 10.24 g of trichloroacetic acid in ml of tert-butyl ether is added over 30 min. to 26 g of the mixture from the above stage in 155 ml of tert-butyl ether. The solution obtained is stirred for 2 hours at 0 C and then for 2 hours at 5 0 C. 12.63 g of the isomer are obtained in the form of the trichloroacetic acid salt.
[aD] -7205 (c 1% CH3CH) NMR (CDC13 250 MHz) 1.15 CH2CH3 1.75 J=7) CH3 (-NH-CH(CH3) (Ph)) 2.78 (dd, J=8.5 and 18.5) 3.05 (dd, J=4 and 18.5) CH2 at 3 of the furanone 3.43 (ddd, J=2-4 and 8.5) CH at 4 of the furanone 3.59 (dq 1H) 3.79 (dq 1H) CH2CH3 4.29 J=7) (-NH-CH(CH3) (Ph)) 5.77 J=1.5) CH at 5 of the furanone 7.42 to 7.57 5H aromatic 9.80 (broad m) H mobile b) production of the trans diastereoisomer -dihydro-5-ethoxy-4- (-phenylethyl)amino] 2(3H)-furanone chloroacetate the mother liquors from the above stage are washed with saturated sodium bicarbonate solution and then re-extracted with tert-butyl ether. After drying, the solution is evaporated under reduced pressure to give 17.43 g of the expected product in the form of an oil. 130 ml of isopropanol are added, followed by 5 g monochloroacetic acid, and the mixture is heated to 40 0 C. Dissolution and then crystallization are observed, after which the mixture is stirred for one hour at room temperature then for two hours at 0-5 0
C.
12.48 g of the expected (4S,5S) isomer are obtained in the form of the monochloroacetic acid salt.
[aD] +10 (c 1% NMR (CDC13 250 MHz) 1.12 J=7.5) CH2CH3 1.26 J=6.5) CH3 (-NH-CH(CH3) (Ph)) 2.18 (dd, J=2.5 and 17.5) 2.66 (dd, J=7.5 and 17.5) CH2 at 3 of the furanone 2.95 (ddd, J=1-2.5 and 7.5) CH at 4 of the furanone 3.66 CH2CH3 3.87 J=6.5) CH (-NH-CH(CH3) (Ph)) 5.42 J=1) CH of the furanone 7.24 1H, 7.33 4H H aromatic 4.26 X-CH2 Stage 3: production of the desalified (4S,5S) compound 4(S) -dihydro-5-ethoxy-4- (1-phenylethyl) amino] 2(3H)-furanone 12.35 g of the salt obtained in Stage 2B and 130 ml of dichloromethane are mixed together at 0-5 0 C, followed by addition of 100 ml of saturated sodium bicarbonate solution.
After stirring for 10 min., the mixture is extracted, washed, dried and evaporated under reduced pressure to give 8.9 g of the desalified product.
[aD] (c 1% Stage 4: epimerization: production of the (4S,5R) diastereoisomer -dihydro-5-ethoxy-4- (-phenylethyl)amino] 2(3H)-furanone 37 ml of 1M tin tetrachloride in dichloromethane are added, under an inert atmosphere over 45 minutes at 0-5 0 C, to 8.8 g of the desalified (4S,5S) compound obtained in Stage 3 in 175 ml of dichloromethane, and the resulting mixture is stirred for 1 hour at this temperature. 14.1 ml of acetic acid are then added, this mixture is stirred for 1 hour at 0- 0 C, poured into a water/ice mixture and washed, cyclohexane is added, this mixture is brought to pH 7-8 by addition of sodium bicarbonate, and it is extracted with cyclohexane, dried and evaporated under reduced pressure to give 3.96 g of the expected product in the form of an oil corresponding to a 90/10 cis/trans ratio.
NMR (CDC13 250 MHz) 1.29 CH2CH3 1.35 CH3 (-NH-CH(CH3) (Ph)) 2.28 (dd, J=11.5 and 17) 2.43 (dd, J=8 and 17) CH2 at 3 of the furanone.
3.36 (ddd, J=4.5/8/1.5) CH at 4 of the furanone 3.67 (dq) 3.92 (dq) CH2CH3 3.81 CH (-NH-CH(CH3) (Ph)) 5.79 J=4.5) CH at 5 of the furanone 7.20 to 7.40 5H aromatic Stage 5: formation of the trichloroacetic acid salt of the cis diastereoisomer 4(S) ,5a] -dihydro-5-ethoxy-4- [(1-phenylethyl) amino] 2(3H)-furanone trichloroacetate 2.34 g of trichloroacetic acid are added, under an inert atmosphere, at 20-25 0 C, to 3.8 g of the cis diastereoisomer obtained in the above stage in 40 ml of tertbutyl methyl ether. The mixture is left for 1 hour at 0-5 0
C
to give 5.58 g of the expected product.
[aD] -49o (c 0.9% Stage 6: hydrogenolysis a) desalification (return to the free amine) -dihydro-5-ethoxy-4- (-phenylethyl)amino] 2(3H)-furanone 5.41 g of the trichloroacetic acid salt obtained in the above stage, 50 ml of cyclohexane and 50 ml of saturated sodium bicarbonate solution are mixed together at 0-5C under an inert atmosphere, the mixture is stirred until dissolved, and it is washed, extracted, dried and evaporated under reduced pressure to give 3.18 g of desalified product in the form of an oil.
[aD] -930 (c 0.62% CH 3 0H) This product is re-purified by mixing 2.85 g of this product with 30 ml of cyclohexane and 2.8 g of silica for 14 J RA3 min. After treatment 2.3 g of a colourless oil are collected.
b) formation of the hydrochloride ,5a] -dihydro-5-ethoxy-4- (-phenylethyl) amino]- 2(3H)-furanone hydrochloride 4 ml of 2N hydrochloric acid in isopropyl ether are added dropwise, at 0-5 C, to 2 g of the product obtained above in 40 ml of isopropyl ether, and the mixture is maintained for 15 minutes at this temperature. The mixture is evaporated under reduced pressure to give 2.29 g of the expected hydrochloride.
c) hydrogenolysis (4(S)-cis)-4-amino-5-ethoxy-dihydro-2(3H)-furanone hydrochloride 1 ml of water then 300 mg of 10% palladium-on-charcoal are added to a suspension of 2.29 g of the hydrochloride obtained above in 40 ml of tetrahydrofuran. The mixture is stirred under 1.5 bar of hydrogen for 5 hours. After filtration and rinsing with a tetrahydrofuran/water mixture, the resulting mixture is evaporated under reduced pressure at 1.40 g of the expected product are obtained.
[aD] -8704 1.22 CH2CH3 2.58 (dd, J=8 and 2.70 (dd, J=8 and 17.5) CH2 at 3 of the furanone 4.14 (dt, J=5.5 and 8) CH at 4 of the furanone 3.61 to 3.9 CH2CH3 5.71 J=5.5) CH at 5 of the furanone 8.69 (bs) mobile 3H's Stage 7: Formation of the allyl carbamate (2R-cis) 2-propenyl (2-ethoxytetrahydro-5-oxo-3-furanyl)carbamate 1 ml of 99% allyl chloroformate then 2 ml of pyridine are added at under an inert atmosphere, to 1.3 g of the product obtained in the above stage in 50 ml of dichloromethane, the mixture is stirred for 1 hour 40 min. at this temperature and 0.3 ml of allyl chloroformate and 0.6 ml of pyridine are then added. This mixture is stirred for 16 hours at room temperature, poured into water, extracted with dichloromethane, washed, dried and evaporated under reduced pressure to give 1.62 g of crude product, which product is recrystallised from isopropyl ether. 1.34 g of the expected product are obtained.
[aD] -52.40 CH2C12) 1.26 CH2CH3 2.47 (dd, J=10 and 17.5) 2.84 (dd, J=8.5 and 17.5) CH2 at 3 of the furanone 3.67 (dq) and 3.92 (dq) CH2CH3 4.55 CH at 4 of the furanone 4.59 (bd) CH2-CH=CH2 5.45 J=5.5) CH at 5 of the furanone 5.25 (dq) and (5.33 (dq) CH2-CH=CH2 5.30 masked N-H 5.93 CH2-CH=CH2 EXAMPLE 3: 4(S)[4a(S*),5a]-dihydro-5-ethoxy-4-[(1phenylethyl) amino]-2(3H)-furanone dichloroacetate Stage 1: Michael Addition dihydro-5-ethoxy-4 [(1-phenylethyl)amino]-2(3H)furanone ml of R-(+)-l-phenylethylamine (19.06 g) are added over about 1 h 30 min., with stirring and under a nitrogen atmosphere, to a solution of 20 g of racemic ethoxyfuranone in 156.8 ml of isopropanol and 3.2 ml of water, while maintaining the temperature of 0+2 0 C, and the resulting mixture is stirred for 24 hours at this temperature.
Stage 2: resolution of the two trans diastereoisomers: production of the trans diastereoisomer 4(S) -dihydro-5-ethoxy-4- [(l-phenylethyl) amino] 2(3H)-furanone trichloroacetate A solution composed of 25.55 g of trichloroacetic acid in 39.2 ml of isopropanol and 0.8 ml of demineralized water is added to the above solution (the product is not isolated), the temperature is allowed to rise to 20-22 0 C, and crystallization of the salt is observed after the end of the introduction. This suspension is maintained for 24 hours at 20+2 0
C,
and the product is then spin-dried and washed with isopropanol containing 2% water. 18 g of the expected product are obtained.
1.15 O-CH2-CH3 1.75 J=7) Ph-CH(CH3)-N 2.78 (dd, J=8.5 and 18.5) CH2 at 3 3.05 (dd, J=4 and 18.5) 3.43 (ddd, J=2.4 and 8.5) H4 3.59 (dq) 1H, 3.79 (dq) 1H O-CH2-CH3 4.29 J=7) Ph-CH(CH3)-N 5.77 J=1.5) Hs 7.42 to 7.57 (5H) H aromatic 9.80 broad H mobile.
Stage 3: epimerization: production of the (4S,5R) diastereoisomer 4(S) ,5a]-dihydro-5-ethoxy-4-[ (1-phenylethyl)amino] 2(3H)-furanone ml of methanesulphonic acid are added, under nitrogen, while maintaining the temperature at 20 2 0 C, to a suspension of 50 g of the (4S,5S) trichloroacetate obtained in the above stage in 150 ml of toluene, the mixture is maintained for 2 hours at 20+2 0 C and, after lowering the temperature to 0+5 0 C, 111 ml of triethylamine are added over 1 h 30 min. After a series of washing, extraction and drying, 400 ml of a solution containing an 85/15 mixture of cis/trans isomer are obtained.
Stage 4: formation of the dichloroacetic acid salt of the cis diastereoisomer 4(S) -dihydro-5-ethoxy-4-[ (-phenylethyl)amino]- 2(3H)-furanone dichloroacetate ml of dichloroacetic acid are added to 400 ml of the above solution, this mixture is concentrated to 6 volumes, 4^\2 ^i WO 99/03852 27 PCT/FR98/01480 crystallization is observed, and stirring is maintained at 20±2 C for 2 hours under nitrogen. After washing with toluene, 32.8 g of the expected product are obtained.
1.21 O-CH2-CH3 1.72 J=6.5) Ph-CH(CH3)-N 2.77 (dd, J=8.5 and 17) CH2 at 3 2.97 (dd, J=ll and 17) 3.76 H4 3.34 3.66 (dq) O-CH2-CH3 4.27 J=6.5) Ph-CH(CH3)-N 4.88 J=5) Hs 5.95 CHC12 7.42 3H, 7.51 2H H aromatic.
9.79 (bs) 2H mobile.
Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification, they are to be interpreted as specifying the presence of the stated features, integers, steps or components referred to, but not to preclude the presence or addition of one or more other feature, integer, step, component or group thereof.
0*
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9708932A FR2766188B1 (en) | 1997-07-15 | 1997-07-15 | NOVEL PROCESS FOR THE PREPARATION OF AMINO DERIVATIVES OF ALKYLOXY FURANONE, COMPOUNDS ARISING FROM THIS PROCESS AND USE OF SUCH COMPOUNDS |
| FR97/08932 | 1997-07-15 | ||
| PCT/FR1998/001480 WO1999003852A1 (en) | 1997-07-15 | 1998-07-09 | Method for preparing alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU8633398A AU8633398A (en) | 1999-02-10 |
| AU744272B2 true AU744272B2 (en) | 2002-02-21 |
Family
ID=9509210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU86333/98A Expired AU744272B2 (en) | 1997-07-15 | 1998-07-09 | Method for preparing alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6235899B1 (en) |
| EP (1) | EP0998470B1 (en) |
| JP (1) | JP4450987B2 (en) |
| KR (1) | KR100519691B1 (en) |
| CN (1) | CN100363355C (en) |
| AP (1) | AP1071A (en) |
| AR (1) | AR015924A1 (en) |
| AT (1) | ATE239713T1 (en) |
| AU (1) | AU744272B2 (en) |
| BG (1) | BG64050B1 (en) |
| BR (1) | BR9810896A (en) |
| CA (1) | CA2296742C (en) |
| CZ (1) | CZ295312B6 (en) |
| DE (1) | DE69814395T2 (en) |
| DK (1) | DK0998470T3 (en) |
| EA (1) | EA002883B1 (en) |
| EE (1) | EE03873B1 (en) |
| ES (1) | ES2197489T3 (en) |
| FR (1) | FR2766188B1 (en) |
| HR (1) | HRP20000027B1 (en) |
| HU (1) | HU230148B1 (en) |
| ID (1) | ID23784A (en) |
| IL (1) | IL134031A (en) |
| ME (1) | ME01708B (en) |
| NO (1) | NO324508B1 (en) |
| NZ (1) | NZ502338A (en) |
| PL (1) | PL200820B1 (en) |
| PT (1) | PT998470E (en) |
| RS (1) | RS49832B (en) |
| SK (1) | SK284168B6 (en) |
| TR (1) | TR200000117T2 (en) |
| UA (1) | UA66364C2 (en) |
| WO (1) | WO1999003852A1 (en) |
| ZA (1) | ZA986203B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053056B2 (en) | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| DE60142470D1 (en) | 2000-04-24 | 2010-08-12 | Vertex Pharma | METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF SUBSTITUTED ASPARAGINIC ACETALES |
| PE20011350A1 (en) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROPHARMAC OF AN INHIBITOR OF INTERLEUKIN-1ß CONVERTER ENZYME (ICE) |
| JP2003327568A (en) * | 2000-09-20 | 2003-11-19 | Kanegafuchi Chem Ind Co Ltd | METHOD FOR PRODUCING OPTICALLY ACTIVE beta-AMINO ACID DERIVATIVE |
| JPWO2002055478A1 (en) * | 2001-01-16 | 2004-05-13 | 鐘淵化学工業株式会社 | Process for producing optically active aminolactone derivatives and intermediates thereof |
| AU2005219861B2 (en) | 2004-02-27 | 2011-08-11 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| ES2533991T3 (en) * | 2004-03-12 | 2015-04-16 | Vertex Pharmaceuticals Incorporated | Processes and intermediate products for the preparation of aspartic caspase acetal inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
-
1997
- 1997-07-15 FR FR9708932A patent/FR2766188B1/en not_active Expired - Lifetime
-
1998
- 1998-07-09 JP JP2000503076A patent/JP4450987B2/en not_active Expired - Lifetime
- 1998-07-09 US US09/463,014 patent/US6235899B1/en not_active Expired - Lifetime
- 1998-07-09 BR BR9810896-4A patent/BR9810896A/en not_active Application Discontinuation
- 1998-07-09 ME MEP-2000-15A patent/ME01708B/en unknown
- 1998-07-09 CA CA002296742A patent/CA2296742C/en not_active Expired - Lifetime
- 1998-07-09 CZ CZ200065A patent/CZ295312B6/en not_active IP Right Cessation
- 1998-07-09 EE EEP200000024A patent/EE03873B1/en unknown
- 1998-07-09 EA EA200000127A patent/EA002883B1/en not_active IP Right Cessation
- 1998-07-09 HU HU0003857A patent/HU230148B1/en unknown
- 1998-07-09 IL IL13403198A patent/IL134031A/en not_active IP Right Cessation
- 1998-07-09 RS YUP-15/00A patent/RS49832B/en unknown
- 1998-07-09 TR TR2000/00117T patent/TR200000117T2/en unknown
- 1998-07-09 DE DE69814395T patent/DE69814395T2/en not_active Expired - Lifetime
- 1998-07-09 ES ES98937591T patent/ES2197489T3/en not_active Expired - Lifetime
- 1998-07-09 SK SK30-2000A patent/SK284168B6/en not_active IP Right Cessation
- 1998-07-09 KR KR10-2000-7000398A patent/KR100519691B1/en not_active IP Right Cessation
- 1998-07-09 WO PCT/FR1998/001480 patent/WO1999003852A1/en active IP Right Grant
- 1998-07-09 AU AU86333/98A patent/AU744272B2/en not_active Expired
- 1998-07-09 CN CNB98808967XA patent/CN100363355C/en not_active Expired - Lifetime
- 1998-07-09 ID IDW20000067A patent/ID23784A/en unknown
- 1998-07-09 DK DK98937591T patent/DK0998470T3/en active
- 1998-07-09 AT AT98937591T patent/ATE239713T1/en active
- 1998-07-09 NZ NZ502338A patent/NZ502338A/en not_active IP Right Cessation
- 1998-07-09 PT PT98937591T patent/PT998470E/en unknown
- 1998-07-09 AP APAP/P/2000/001732A patent/AP1071A/en active
- 1998-07-09 EP EP98937591A patent/EP0998470B1/en not_active Expired - Lifetime
- 1998-07-09 PL PL338035A patent/PL200820B1/en unknown
- 1998-07-13 ZA ZA9806203A patent/ZA986203B/en unknown
- 1998-07-15 AR ARP980103455A patent/AR015924A1/en not_active Application Discontinuation
- 1998-09-07 UA UA2000020800A patent/UA66364C2/en unknown
-
2000
- 2000-01-12 BG BG104073A patent/BG64050B1/en unknown
- 2000-01-14 NO NO20000182A patent/NO324508B1/en not_active IP Right Cessation
- 2000-01-14 HR HR20000027A patent/HRP20000027B1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2492540C (en) | Modified pictet-spengler reaction and products prepared therefrom | |
| FI87196C (en) | EXAMINATION OF FRAMSTAELLNING AV (Z) -1-PHENYL-1-DIETHYLAMINOCARBONYL-2-AMINOMETHYLCYCLOPROPHYL CHLORIDE | |
| CZ258794A3 (en) | Process for preparing indanylamine compounds | |
| AU744272B2 (en) | Method for preparing alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds | |
| EP0234561A2 (en) | 2,3-Dihydro-2-phenyl-5-aminoalkyl-naphtho [1,2-b]-1,4-thiazepin-4(5H)-one derivatives | |
| US4963671A (en) | Process for resolving chiral intermediates used in making calcium channel blockers | |
| FI81339C (en) | FOERFARANDE FOER FRAMSTAELLNING AV PYRROLIDINODERIVAT, MELLANPRODUKT OCH DESS FRAMSTAELLNINGSFOERFARANDE. | |
| GB1598667A (en) | 1,3-dioxolane derivatives and their use in the preparation of 1-amino-3-aryloxy-2-propanols | |
| Pyne et al. | Diastereoselective addition of α-hydroxyalkyl and α-alkoxyalkyl radicals to chiral 4-methyleneoxazolidin-5-ones | |
| JP2001521498A (en) | Method for producing O- (3-amino-2-hydroxy-propyl) -hydroxymic acid halide | |
| KR100404965B1 (en) | Novel Hydantoin Library Using Combinatorial Chemistry | |
| US5550288A (en) | Process for the preparation of α-aminoacylanilides | |
| MXPA00000506A (en) | Method for preparing alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds | |
| US6355804B1 (en) | Process for producing piperidinecarboxylic acid amide derivatives | |
| CA2409614C (en) | Separation of the enantiomers of piperidone derivatives with simultaneous racemisation in situ of the unwanted enantiomer | |
| KR20040080039A (en) | Improved method for the preparation of intermediate of amlodipine | |
| KR20050115948A (en) | Method for production of 4,10β-diacetoxy-2α-benzoyloxy-5β,20-epoxy-1,13α-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene | |
| SK1262003A3 (en) | Process for the preparation of 9-amino substituted 9,10-dihydropyrrolo [2,1-B][1,3]benzothiazepines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |